Welcome to our dedicated page for FRACTYL HEALTH SEC filings (Ticker: GUTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FRACTYL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FRACTYL HEALTH's regulatory disclosures and financial reporting.
FRACTYL HEALTH, INC. director Christopher Charles Thompson received a grant of stock options covering 22,500 shares of common stock as compensation for his service on the board under the non-employee director compensation policy. The options have an exercise price of $0.7318 per share and expire on June 9, 2036. They vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, subject to his continued service as a non-employee director. Following this award, he holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Marc Elia received a stock option grant covering 22,500 shares of common stock as compensation for board service. The option has an exercise price of $0.7318 per share and expires on June 9, 2036.
The award will vest and become exercisable in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to Elia’s continued service as a non-employee director. After this grant, he holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Kelly Ann Barnes received a grant of stock options covering 22,500 shares of common stock as compensation for her board service. The options have an exercise price of $0.7318 per share and expire on June 9, 2036.
According to the terms, the award will vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, in each case subject to her continued service as a non-employee director. Following this grant, she holds 22,500 options directly.
FRACTYL HEALTH, INC. director Clive Meanwell received a grant of stock options as part of his non-employee director compensation. The award covers 22,500 options for common stock at an exercise price of $0.7318 per share, expiring on June 9, 2036.
The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, assuming continued service on the board. Following this grant, Meanwell holds 22,500 stock options directly, with no open-market purchases or sales reported.
FRACTYL HEALTH, INC. director Ian Sheffield reported an open-market purchase and an option grant. He bought 35,000 shares of Common Stock at $0.7294 per share, giving him 35,000 shares held directly after the transaction.
He was also granted 22,500 stock options with an exercise price of $0.7318 per share, each for one share of Common Stock and expiring on June 9, 2036. The option vests in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to his continued service on the board as a non-employee director.
Fractyl Health, Inc. Chief Executive Officer Harith Rajagopalan reported an open-market purchase of 25,000 shares of common stock on June 10, 2026 at a weighted average price of $0.7301 per share, with trade prices ranging from $0.7213 to $0.7324.
Following this transaction, he directly holds 540,557 shares of common stock and indirectly holds additional shares through three trusts with reported positions of 18,639, 292,170, and 292,171 shares. His holdings also include 13,812 shares purchased under the company’s 2024 Employee Stock Purchase Plan on January 30, 2026 at $0.391 per share.
FRACTYL HEALTH, INC. Chief Financial Officer Lara Smith Weber reported an open-market purchase of 20,000 shares of common stock. The shares were bought on June 8, 2026 at a weighted average price of $0.6854 per share, in multiple trades between $0.6844 and $0.6896. Following this transaction, she directly owns 20,000 common shares.
Fractyl Health reported encouraging one-year results from its open-label REVEAL-1 Cohort evaluating the Revita procedure in people with obesity who stopped GLP-1 drugs after losing at least 15% of body weight. Participants had lost about 24% total body weight on GLP-1 therapy before enrollment.
After a single Revita procedure, patients retained roughly 78% of that GLP-1-induced weight loss at one year, with a mean total body weight change of 5.3% and 33% of participants continuing to lose weight. All patients maintained at least 5% of their prior weight loss.
Glycemic control was stable, with an HbA1c change of 0.08%, and there were no procedure-related serious adverse events. Mild treatment-emergent events occurred in 36% of participants, were transient, and appeared within the first month. Fractyl expects randomized REMAIN-1 data readouts in Q3 and early Q4 2026.
Fractyl Health, Inc. ownership disclosure: Nantahala Capital Management, LLC and its two managing members report beneficial ownership of 16,124,780 shares of Common Stock as of March 31, 2026, representing 9.99% of the class. The holdings include 2,760,261 shares that may be acquired within sixty days through the exercise of convertible securities. The filing states shared voting and dispositive power for Nantahala, Wilmot B. Harkey and Daniel Mack; sole voting and dispositive power are reported as zero.
683 Capital Management, 683 Capital Partners and Ari Zweiman report beneficial ownership in Fractyl Health, Inc. As of March 31, 2026 the filing shows 6,727,235 shares plus 952,380 currently exercisable warrants attributable to the Reporting Persons, totaling 7,679,615 shares, or 4.81% of the company's common stock based on 158,648,963 shares outstanding per the issuer's Form 10-K.
The Schedule 13G/A notes shared voting and dispositive power for the reported shares and lists the Reporting Persons' principal address. The filing is an amended beneficial-ownership disclosure reflecting holdings as of the stated dates.